Table 2.
Lewis et al.: Iron Parameters After 52-week Safety Assessment Period, Ferric Citrate Versus Active Control 19,20
| Baseline Mean (SEM) | Week 52 Mean (SEM) | Week 52 Median or Cumulative Median (25th–75th Percentile) | ANCOVA or Wilcoxon Rank Sum Results (Ferric Citrate Versus Active Control) | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Ferric Citrate | Active Control | Ferric Citrate | Active Control | Ferric Citrate | Active Control | Adjusted Mean Difference | 95% Confidence Interval | P Value | |
| Ferritin (ng/mL) | 593 (18) | 609 (26) | 899 (31) | 628 (31) | 858 (568–1,105) | 576 (333–883) | 282 | 197 to 366 | < 0.001 |
| TSAT (%) | 31.3 (0.7) | 30.9 (1.0) | 39.3 (1.1) | 29.7 (1.0) | 36.0 (27.5–47.0) | 28.0 (21.0–34.5) | 9.5 | 6.4 to 12.6 | < 0.001 |
| IV iron requirements (mg/week) | − | − | − | − | 12.9 (1.0–28.9) | 26.8 (13.4–47.6) | −12.5 | −17.2 to −7.9 | < 0 .001 |
| ESA dose (units/week) | − | − | − | − | 5,303 (2,023–9,695) | 6,954 (2,664–12,375) | −1,191 | −2,632 to 0 | 0.04 |
ESAs = erythropoietin-stimulating agents; IV = intravenous; SEM = standard error of the mean; TSAT = transferrin saturation